Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Bollinger Bands

Score

-0.9

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 30 14.3 0.27% 0.36% 22.7% -3.3% 107.8%
SHORT 31 11.5 0.13% 0.15% 5.0% -4.8% -109.1%

Summary

Technical Analysis


The purpose of the Bollinger Bands is to provide a relative definition of high and low. By definition prices are high at the upper band and low at the lower band. This definition can aid in rigorous pattern recognition and is useful in comparing price action of the action of indicators to arrive at systematic trading decision.

Calculation: Bollinger Bands:
1) Middle Band = 20-day simple moving average (SMA);
2) Upper Band = 20-day SMA + (20-day standard deviation of price x 2);
3) Lower Band = 20-day SMA - (20-day standard deviation of price x 2);


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Bollinger Bands

Download
Company Close Change(%) Volume Value Signal
INO Inovio Pharma 4.36 9.3 34,675,337 5.43 BULLISH
VIVO Meridian Bioscience 8.16 9.2 1,886,706 53.78 BULLISH
STAA Staar Surgical 31.05 8 1,662,302 57.25 BULLISH
DLTH Duluth Holdings 7.39 5.1 226,062 3.23 BULLISH
HSII Heidrick & Struggles 22.2 3.8 207,252 24.75 BULLISH
CLDX Celldex Therapeutics 2.71 3.8 455,237 42.68 BULLISH
SYRS Syros Pharmaceuticals 6.65 3.3 129,382 36.04 BULLISH
EZPW Ezcorp Inc 4.79 2.4 1,002,907 18.18 BULLISH
WIRE Encore Wire 50.87 2.3 196,575 43.09 BULLISH
SBLK Star Bulk Carriers 8.18 2.1 545,828 16.5 BULLISH